Science Spotlight: Making in vivo CAR T less immunogenic

Researchers at the Broad Institute of MIT and Harvard engineered a lentiviral vector that can slip past measles vaccine immunity, removing a major barrier to in vivo CAR T deployment in previously vaccinated patients.

Routine measles vaccines rely on live‑attenuated measles virus to induce antibodies against measles H and F glycoproteins, and those same H/F proteins are powerful lentiviral-targeting modules that have been hard to use in humans because pre-existing antibodies can neutralize the vector. ...